Compare Amylx Pharmaceuticals Inc (AMLX) vs Match Group Inc (MTCH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Match Group Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Match Group Inc trades at $39.87 (market cap $9.06B). The key difference: Match Group Inc is far larger — about 4.6× Amylx Pharmaceuticals Inc's market cap, and Match Group Inc pays a 2.06% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MTCH | |
|---|---|---|
Market Cap | $1.98B | $9.06B |
Sector | Health | Media |
52-Week High | $18.70 | $39.32 |
52-Week Low | $7.64 | $28.90 |
Enterprise Value | $1.70B | $12.01B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
MTCH trades at $38.85, down 1.2% today, with a bullish technical signal from moving averages and key support at $38. The company shows solid fundamentals with a P/E of 14.83, net income margin of 18.83%, and three consecutive quarterly earnings beats. Revenue growth remains stable at $3.49B for 2025, while cash flow from operations improved to $1.08B. Recent news highlights a turnaround focus, including Tinder's AI features and Hinge's growth.
The outlook is positive with a consensus price target of $41.63, implying 7% upside. Analyst sentiment is bullish (53% Buy), but risks include high long-term debt of $3.85B and competitive pressures in dating apps. Earnings growth and debt management are critical for sustained stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
